Darunavir and Rivaroxaban (Xarelto 2.5 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
CYP3A and transporter inhibition increases rivaroxaban exposure.
Clinical significance and safety
For ritonavir-boosted darunavir (PREZISTA/ritonavir), rivaroxaban is not recommended because bleeding risk may increase. The prescriber must review anticoagulation rather than the patient independently stopping treatment.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.